ArticleMolecular cell2024
Phage anti-CBASS protein simultaneously sequesters cyclic trinucleotides and dinucleotides.
Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Cyclic tri-adenylate controls a CARF-TM effector in type II Panoptes anti-phage systems.PLoS biology · 2026Article
- Phage-encoded NARP3 system rebuilds NADScience advances · 2026Article
- Inhibition by ATP regulates the activity of a CBASS anti-phage nucleotide cyclase.The Biochemical journal · 2026Article
- Article
- Genome annotation ofMicrobiology resource announcements · 2026Article
- Crystal structure of the cytosolic Nudix-like domain of CD-NTase-associated protein 16 from Enterococcus faecalis.Acta crystallographica. Section F, Structural biology communications · 2026Article
- Balancing of immune activation and suppression during phage infection.bioRxiv : the preprint server for biology · 2026Article
- Functional diversity of phage sponge proteins that sequester host immune signals.Nature microbiology · 2026Article
- The CRISPR ring nuclease Csx15 oligomerises on cyclic nucleotide binding to regulate antiviral defence.The Biochemical journal · 2026Article
- A phage-encoded sponge protein suppresses bacterial TIR-Caspase immune signaling.Nature communications · 2026Article
- Systematic discovery of bacterial anti-phage systems through a protein domain-centric strategy.Nucleic acids research · 2026Article
- Periplasmic gatekeeping of phage DNA entry by an rSAM enzyme matured effector with HxS repeats.Nature communications · 2026Article
- Article
- Manipulation of the nucleotide pool in human, bacterial and plant immunity.Nature reviews. Immunology · 2026Review
- Bacteriophage genome-wide transposon mutagenesis.bioRxiv : the preprint server for biology · 2025Article
- The complex developmental mechanisms of nucleus-forming jumbo phages.Current opinion in microbiology · 2025Review
- Genomic islands inNAR genomics and bioinformatics · 2025Article
- A viral SAVED protein with ring nuclease activity degrades the CRISPR second messenger cA4.The Biochemical journal · 2025Article
- Article
- Article
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Cyclic-oligonucleotide-based anti-phage signaling system (CBASS) is a common immune system that uses cyclic oligonucleotide signals to limit phage replication. In turn, phages encode anti-CBASS (Acb) proteins such as Acb2, which can sequester some cyclic dinucleotides (CDNs) and limit downstream effector activation. Here, we identified that Acb2 sequesters many CDNs produced by CBASS systems and inhibits stimulator of interferon genes (STING) activity in human cells. Surprisingly, the Acb2 hexamer also binds with high affinity to CBASS cyclic trinucleotides (CTNs) 3'3'3'-cyclic AMP-AMP-AMP and 3'3'3'-cAAG at a distinct site from CDNs. One Acb2 hexamer can simultaneously bind two CTNs and three CDNs. Phage-encoded Acb2 provides protection from type III-C CBASS that uses cA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.